{"id":"NCT01138007","sponsor":"GlaxoSmithKline","briefTitle":"A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)","officialTitle":"Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-17","primaryCompletion":"2012-08-01","completion":"2012-08-07","firstPosted":"2010-06-07","resultsPosted":"2013-05-06","lastUpdate":"2018-08-10"},"enrollment":572,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"323U66 SR 150 mg tablet","otherNames":[]},{"type":"DRUG","name":"323U66 SR 150 mg placebo tablet","otherNames":[]}],"arms":[{"label":"323U66 SR 150 mg cohort","type":"EXPERIMENTAL"},{"label":"323U66 SR 300 mg cohort","type":"EXPERIMENTAL"},{"label":"Placebo cohort","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at doses level of 150 mg/day and 300 mg/day for 8 weeks based on the decrease in MADRS (Montgomery-Asberg Depression Rating Scale) total score, and to evaluate the safety based on adverse events, clinical laboratory tests and vital signs.","primaryOutcome":{"measure":"Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal","timeFrame":"Baseline and Week 8/Withdrawal","effectByArm":[{"arm":"Placebo","deltaMin":-13.9,"sd":0.77},{"arm":"323U66 SR 150 mg","deltaMin":-14.4,"sd":0.77},{"arm":"323U66 SR 300 mg","deltaMin":-12.9,"sd":0.76}],"pValues":[{"comp":"OG000 vs OG001","p":"0.853"},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":30},"locations":{"siteCount":59,"countries":["Japan","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":186},"commonTop":["Nasopharyngitis","Dry mouth","Headache","Nausea","Constipation"]}}